Abstract
Overview
Introduction
Datamonitor predicts a somewhat enthusiastic uptake of two agents currently in
development by 2015. However, reimbursement is critical to the uptake of new
medication, due to the high cost of therapy. If the reimbursable status is not
achieved, the expansion of the market will not match the rate of growth of the
obese population and the great potential of the obesity market will remain
untapped.
Scope
- Assessment of the patient potential for developmental anti-obesity agents
over the period 2006-15
- Overview of the anti-obesity R&D pipeline, with detailed information on
the classes in development and comparator drugs
- Commercial analysis of key compounds in development regarding their
ability to take away market share from the currently available drugs
- Sales forecasts for key late-stage developmental anti-obesity agents in
the seven major markets to 2015
Highlights
The obesity "epidemic" is taking place to a certain extent in all the major
markets, and the rate of obesity prevalence growth is not showing any signs of
slowing down in the near future.
The anti-obesity market growth does not follow the growth of obesity
prevalence. The major cause for the lack of growth in most of the major
markets is lack of reimbursement for pharmacological management of obesity.
The drugs currently available in the major markets for treatment of obesity
have significant unmet needs and do not meet the expectations of obese
patients. The pipeline drugs will be able to expand the market. However, the
growth of the market will still be marginal in comparison to the growth of
obesity prevalence.
Reasons to Purchase
- Understand the key factors that will contribute to the success of the next
generation of anti-obesity drugs
- View independent sales forecasts for products in late stage development
for therapy of obesity
- Understand physician sentiment on clinical trial endpoints and late-stage
candidate drugs for the obesity market
| 
View Cart
